Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
Keytruda is the US’s first-to-market therapy that targets the programmed cell death receptor-1 (PD-1), better enabling the immune system to fight cancer. However, according to GlobalData’s Fenix Leung, BMS’s Opdivo could receive approval from the European Medicines Agency for first-line melanoma treatment as early as Q2 2015.
Leung added that BMS is clearly working on a tight deadline to push Opdivo ahead of Keytruda in the EU.
Opdivo’s Phase III CheckMate-067 trial included an investigation of a Yervoy/Opdivo combination, which showed unmatched efficacy in a Phase 1b trial. The median overall survival of patients was 40 months, more than double that of either drug alone.
Leung commented: “Combination strategies are essential in the race to capture a large share of one of the most promising markets in cancer immunotherapy… Nonetheless, we will need to wait for the safety results from the CheckMate-067 trial, due in the fall of 2016, to gain an improved understanding of the Yervoy/Opdivo combination’s safety profile prior to approval in either the US or EU.”
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.